Last reviewed · How we verify
NCT04280380: CMV-ICU
Cytomegalovirus Infection in Critically Ill Patients and Patients Receiving Anticancer Therapy
trial testing Real time PCR in CMV in 400 participants. Status unknown.
31 December 2021
Quick facts
| Lead sponsor | Fundación de investigación HM |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 400 |
| Start date | 1 March 2020 |
| Primary completion | 31 December 2021 |
| Estimated completion | 31 December 2022 |
Drugs / interventions tested
- Real time PCR
Conditions studied
- CMV — all drugs for CMV →
Sponsor
Fundación de investigación HM — full company profile →
Who can join
18 and older, any sex, with CMV. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cytomegalovirus (CMV) is the most common member of the herpes viruses to infect humans. Its double-stranded linear DNA duplex contains 165 genes that encode viral proteins that mimic and interact with human cellular proteins and are related to its virulence and latency. CMV primary infection is usually acquired in the adolescence and follows a benign course; however it might reactivate in patients with immune suppression leading to a high mortality and morbidity in this group of patients. There is growing evidence that critically ill immunocompetent patients can develop CMV disease \[Limaye et al. JAMA. 2008;300(4):413; Ziemann et al. Crit Care Med. 2008;36(12):3145\]. However, results of the incidence of CMV disease in critically ill patients is unpredictable due to the wide range of these results, from a 0% to 98% \[Al-Omari et al. Ann. Intensive Care (2016) 6:110\]. This inconsistency could be explained by many factors such as (i) variation in the definition of CMV disease (old studies consider seropositivity as evidence of disease, while others use newer technologies like PCR and/or antigen detection), (ii) variation in inclusion criteria (some studies include only seropositive patients therefore assessing reactivation rate of CMV, others also include seronegative patients thus evaluating also new infections) or (iii) variation in studied populations (e.g. septic, surgical, burn or postcardiac surgery patients or patients under mechanical ventilation).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04280380
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Real time PCR
Trials testing the same drug.
- NCT03433768 — Androgen Receptor mRNA Expression is Positively Associated With Live Birth in Women Undergoing IVF Independently of the · completed
Other recruiting trials for CMV
Currently open trials in the same condition.
- NCT06812598 — Efficacy of Extended Letermovir Prophylaxis to Prevent CMV Reactivation in High-Risk Chinese Adults Undergoing Allogenei · NA · recruiting
- NCT06011486 — Expansion of Virus-Specific Lymphocytes for Cell Therapy · Phase 1 · recruiting
- NCT06001320 — De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients · Phase 3 · active not recruiting
- NCT04056533 — Prophylaxis of Cytomegalovirus Infection With Adoptive Cell Inmunotherapy · Phase 2 · recruiting
- NCT01011712 — The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunoco · recruiting
Other Fundación de investigación HM trials
Trials by the same sponsor.
- NCT05914051 — PRELOAD-TAVI Trial · NA · unknown
- NCT06840678 — Home-based Transcranial Static Magnetic Field Stimulation (tSMS) of the Supplementary Motor Area in Parkinson's Disease · Phase 1 · recruiting
- NCT05513755 — Cardioneuroablation in Reflex Syncope (CARDIOSYRE Trial) · NA · unknown
- NCT04692116 — Parkinson's Disease (PD) Treated With Focused Ultrasound Subthalamotomy at an Early Stage · NA · completed
- NCT04525638 — A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours · Phase 2 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04280380 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fundación de investigación HM
- Last refreshed: 21 February 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04280380.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing